Trial Profile

Pharmacoscintigraphic Investigation NN9924 in Healthy Male Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Alzheimer's disease; Obesity; Type 2 diabetes mellitus
Focus Pharmacokinetics
Sponsors Novo Nordisk

Most Recent Events

10 May 2021 Results of pooled analysis assessing clinical pharmacokinetics of oral Semaglutide published in the Clinical Pharmacokinetics
15 Sep 2017 Results of this and other study assessing absorption of semaglutide, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com